Kidney transplantation has become the treatment of choice for both the quality of life and
survival in patients with end-stage renal disease (ESRD). However, the immunosuppressive
regimen which allows optimal kidney transplant outcome remains elusive. One of the more
promising induction agents, Alemtuzumab, was introduced to kidney transplantation by
Calne in the late 1990s with low dose cyclosporine A monotherapy, with the hope of
establishing 'prope'or near tolerance. Subsequent pilot studies with Alemtuzumab alone or …